VSY Biotechnology Research Centre has announced that its drug to treat COVID-19 is now ready for human testing.
The new drug – named TR-C 19 – has been developed to treat COVID-19 by the VSY Biotechnology R&D team. Studies have shown that TR-C 19 can neutralize the virus isolated under laboratory conditions.
The drug is now at the authority approval stage for usage on voluntary COVID-19 patients and clinical trial. Health authorities accelerate their evaluation of TR-C 19 considering public health emergency conditions.
Clinical and voluntary trials will be organised in partnership with SBU. The initial results of voluntary patient trials will be shared publicly in the coming weeks.